We previously identified a cluster of prostanoid receptor genes, prostaglandin D2 receptor (PTGDR) and prostaglandin E receptor 2 (PTGER2), as possible targets for DNA methylation in advanced types of neuroblastoma (NB) using bacterial artificial chromosome array-based methylated CpG island amplification method. Among them, in this study, we found that PTGER2 was frequently silenced in NB cell lines, especially in those with MYCN amplification, through epigenetic mechanisms. In NB cell lines, DNA methylation pattern within a part of CpG island was inversely correlated with PTGER2 expression, and histone H3 and H4 deacetylation and histone H3 lysine 9 methylation within the putative promoter region were more directly correlated with silencing of this gene. Methylation of PTGER2 was observed more frequently in advancedtype of primary NBs compared with early-stage tumors. Growth of NB cells lacking endogenous PTGER2 expression was inhibited by restoration of the gene product by transient and stable transfection. A PTGER2-selective agonist, butaprost, increased intracellular cyclic adenosine monophosphate (cAMP) level, inhibited cell growth and induced apoptosis of NB cells stably expressing exogenous PTGER2. 8-Bromo-cAMP also inhibited growth of NB cells lacking PTGER2 expression, but not cells expressing this gene. Taken together, it is suggested that NB cells may lose responsiveness to PTGER2-mediated growth inhibition/ apoptosis through epigenetic silencing of PTGER2 and/ or disruption of downstream cAMP-dependent pathway during the neuroblastomagenesis.
Introduction
Neuroblastoma (NB) is one of the most common pediatric solid tumors of neural-crest origin. The outcome of this disease is highly heterogeneous: older patients frequently develop metastatic disease with extremely aggressive progression, whereas spontaneous regression is common in infants and in early-stage NB tumors (Westermann and Schwab, 2002; Brodeur, 2003) . Although numerous genetic abnormalities, including the MYCN amplification, are involved in development and/or progression of NB, the molecular mechanisms responsible for the pathogenesis of aggressive NB remain unclear. Epigenetic alterations such as hypermethylation of promoter sequences, with consequent silencing of tumor-suppressor genes, such as CASP8, RASSF1A, CD44 and TSP-1 can play important roles in the pathogenesis of NB (Teitz et al., 2000; Yan et al., 2003; Yang et al., 2003 Yang et al., , 2004 . Therefore, exploration of hypermethylated CpG-rich sequences in NB cell genomes could accelerate identification of unknown tumor suppressors whose loss contributes to progression of this disease.
Recently, we developed 'bacterial artificial chromosome (BAC) array-based methylated CpG-island amplification (MCA)' (BAMCA; Inazawa et al., 2004) , which incorporates our custom-made BAC-based genomic DNA array (Inazawa et al., 2004) in combination with MCA (Toyota et al., 1999) , as a method for detecting aberrantly methylated sequences in the human genome. When we applied BAMCA to NB genomes using aggressive NB cell lines and stage 1 'nonaggressive' primary NB tumors as test and reference samples, respectively, followed by expression and methylation analyses of candidate targets, we successfully identified NR1I2 as a novel tumor-suppressor candidate that is often silenced by DNA methylation in advanced type of this disease (Misawa et al., 2005) . In the process, we also identified several possible targets other than NR1I2 for methylation-mediated silencing in advanced NB. Since identification of additional epigenetic abnormalities in NB should lead not only to better understanding of the pathogenesis of this disease, but also to development of new diagnostic markers and/or therapeutic strategies (Abe et al., 2005) , determining the significance of each candidate tumor-suppressor gene inactivated by epigenetic mechanisms in NB will be highly valuable. Among possible targets, in the study reported here we analysed two genes, prostaglandin E receptor 2 (PTGER2) and prostaglandin D2 receptor (PTGDR), both are located within the same BAC and encode receptors for subtypes of prostaglandin E2 (PGE2) and D2 respectively, and identified PTGER2 as a candidate tumor suppressor for NB.
Results
Analysis of PTGDR and PTGER2 expression in NB cell lines In our previous report (Misawa et al., 2005) , we described a strategy for identifying epigenetically silenced tumor-suppressor genes through exploration of aberrantly methylated sequences in the NB genome. During that program, PTGDR and PTGER2, within one BAC clone (RP11-262M8) at 14q22.1, were identified as possible targets for inactivation through DNA methylation (Figure 1a ). To determine whether those genes might be silenced in NB, we examined expression of PTGDR and PTGER2 mRNAs in a panel of 20 NB cell lines by reverse transcription (RT)-PCR. Expression of PTGDR was lost or decreased in most of the cell lines compared with normal adrenal gland and brain, whereas PTGER2 expression was lost or decreased in eight lines and detected in 12 lines ( Figure 1b ). All eight lines that lacked expression of PTGER2 showed amplification of MYCN, whereas only five of the 12 PTGER2-expressing lines did (P ¼ 0.015, Fisher's exact test).
Restoration of PTGDR and PTGER2 expression by 5-aza-dCyd and TSA To investigate whether DNA demethylation could restore expression of PTGDR and PTGER2 mRNAs in NB cells lacking them, we treated NB cells with 1 or 5 mM of 5-aza 2 0 -deoxycytidine (5-aza-dCyd), a methyltransferase inhibitor, for 5 days and/or 100 ng/ml of trichostatin A (TSA), a histone deacetylase inhibitor, for the last 12 h. Induction of PTGDR and PTGER2 mRNAs occurred after treatment with 5-aza-dCyd in cells lacking expression of the genes (Figure 1c) . Restoration of mRNA expression was also observed for both genes, especially PTGER2, after treatment with TSA alone. However, a greater elevation in expression was observed in cells treated with 5-aza-dCyd and TSA compared with those treated with 5-aza-dCyd alone, suggesting that DNA methylation and histone modification, including deacetylation of histones, may be cooperatively involved in silencing these two genes.
Methylation of PTGDR and PTGER2 CpG islands in NB cell lines We examined the methylation status of CpG islands of the PTGDR and PTGER2 genes predicted by the CpGPLOT program (http://www.ebi. ac.uk/emboss/ cpgplot/, Figure 2a ). Bisulfite-sequencing revealed aberrant DNA hypermethylation throughout the CpG island of PTGDR in four NB cell lines, regardless of expression levels (Figure 2b ). On the other hand, aberrant DNA hypermethylation was observed within Region 3 and part of Region 2 of the PTGER2 CpG island in three cell lines (IMR32, GOTO and SJ-N-CG) that lack expression of PTGER2, while this island was hypomethylated in SH-SY5Y expressing the gene. We performed combined bisulfite restriction analysis (COBRA) in a larger set of NB cell lines to confirm the relationship between expression and methylation status within the whole CpG island of PTGDR and within Region 3 or part of Region 3 (Region 3-A) of the PTGER2 CpG island (Figure 2b and Supplementary Figure S1 ). Methylated alleles were predominant in most of the NB lines lacking PTGER2 expression, and unmethylated alleles were always detected in cells that expressed this gene. For PTGDR, however, no clear relationship was observed between gene expression and methylation status of the CpG island. These results prompted us to characterize further the PTGER2 gene as a candidate tumor suppressor inactivated through epigenetic mechanism.
Promoter activity of the CpG island of PTGER2 We performed reporter assays to determine whether the CpG island of PTGER2, whose methylation status was inversely correlated with gene expression, possessed promoter activity. Unexpectedly, fragment 3, where methylation was observed in NB cell lines lacking expression of PTGER2, revealed little promoter activity, whereas upstream fragment 1 showed remarkable activity (Figure 2c ), suggesting that methylation within Region 3 of the PTGER2 CpG island may not directly inhibit a promoter activity for gene expression, but indirectly contribute to silencing of PTGER2 through additional epigenetic mechanisms.
Chromatin immunoprecipitation assay
Since the results of our promoter assays suggested that epigenetic mechanisms other than DNA methylation might directly regulate transcription of PTGER2, we postulated that histone acetylation and/or methylation might determine expression of PTGER2 (Wolffe and Matzke, 1999; Schubeler et al., 2000; Jones and Baylin, 2002; Kondo et al., 2003; Nakagawachi et al., 2003; Lorincz et al., 2004; Stirzaker et al., 2004; Strunnikova et al., 2005; Azuara et al., 2006; Frigola et al., 2006; Yamada et al., 2006) , and examined status of histone modification by means of chromatin immunoprecipitation (ChIP) assays using primers designed within the putative promoter region (Figure 2a ). Acetylated histone H3-and H4-binding fragments were decreased in gene-nonexpressing CHP134, SJ-N-CG and GOTO cell lines, as compared with gene-expressing SK-N-AS and SH-SY5Y cell lines (Figure 2d ). On the other hand, the di-and tri-methylated histone H3 lysine 9-(H3K9-) binding fragment was increased in the CHP134, SJ-N-CG and GOTO cell lines compared with SK-N-AS and SH-SY5Y cell lines (Figure 2d ), suggesting that around the promoter region of PTGER2, histones H3 and H4 are hypoacetylated and histone H3K9 is di-and trimethylated in NB cells lacking expression of this gene and those status of histone modification may be associated with DNA methylation within Region 3 of the PTGER2 CpG island. This observation is consistent with the restoration of PTGER2 expression by TSA and the observed synergistic effect of TSA together with 5-aza-dCyd (Figure 1c ).
Methylation and expression of PTGER2 in primary NB tumors To determine whether aberrant methylation of PTGER2 also takes place in primary NBs, we performed methylation analyses in a panel of surgical samples using bisulfite sequencing, COBRA and methylationspecific PCR (MSP). Several stage 4 tumors showed more or less aberrant methylation within Region 3 of the PTGER2 CpG island (Figure 3a and Supplementary Figure S1 ), whereas the control normal adrenal gland or stage 1 and 4S tumors did not. Using primers designed within the Region 3 (Figure 3a ) based on the localization pattern of methylation, we investigated the methylation status of the Region 3 within the PTGER2 Figure 1 PTGER2 and PTGDR are candidate targets for silencing in NB cells through DNA methylation. (a) Genomic structure of the PTGDR and PTGER2 genes within the RP11-262M8 BAC clone, which was detected as one of BAC clones containing abnormally methylated sequences by BAMCA using two NB cell lines (GOTO and IMR32) as test samples and stage 1 NB tumors as control samples (Misawa et al., 2005) . Open and filled boxes represent untranslated and coding exonic sequences respectively; hatched boxes indicate 1479 and 1482 bp CpG islands that exist around exon 1 of each gene, respectively. (b) RT-PCR analysis of PTGDR and PTGER2 mRNAs in normal adrenal gland, normal brain and NB cell lines with ( þ ) or without (À) amplification of MYCN (SaitoOhara et al., 2003) . Expression of GAPDH served as an internal control. (c) Representative results of RT-PCR analysis to reveal PTGDR and PTGER2 mRNA expression in NB cell lines with ( þ ) and without (À) treatment with 5-aza-dCyd and/or TSA, with GAPDH expression as an internal control. PCR products were electrophoresed in 3% agarose gel, and the band quantification was done with LAS-3000 (Fujifilm). Expression levels of PTGDR and PTGER2 mRNA were normalized by that of GAPDH amplified at the same time. Experiments were repeated two times.
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CpG island in all 49 surgically resected primary NBs and two ganglioneuromas. Methylation of Region 3 was detected in 12 of the 49 tumors (24.5%, Figure 3a ), but not in ganglioneuromas. Of those 12 cases, four were in stage 1, 2, 3 and 4S tumors, whereas eight cases were in stage 4 (P ¼ 0.0004, Fisher's exact test; Figure 3b ). The results of the MSP experiments were consistent with those from bisulfite sequencing (Figure 2b) . Notably, eight of the nine tumors (88.9%) with MYCN amplification showed methylation, whereas only four of 40 tumors (10%) without amplification showed methylation (Po0.0001, Fisher's exact test; Figure 3b ).
Expression levels of PTGER2 mRNA in 39 primary NB tumors were evaluated by real-time quantitative RT-PCR. No significant difference was also observed between methylated and unmethylated NB cases as well as between MYCN-amplified and MYCN-unamplified NB cases (P ¼ 0.6932 and 0.7003, respectively, Student's t-test; Figure 3c ). Since we conjectured that nontumorous cells such as leukocytes and endothelial cells might disturb accurate evaluation of expression levels of PTGER2 is a possible neuroblastoma suppressor Y Sugino et al PTGER2 in primary NBs, we performed immunohistochemical analysis using PTGER2-specific antibody to evaluate expression patterns in more detail. Matured ganglion cells in ganglioneuroma ( Figure 3d ) and NB cells differentiating to ganglion-like cells, seen mainly in stage 1 tumors with good prognosis (Figure 3e ), were strongly stained with PTGER2, while the undifferentiated small round cells filling stage 4 tumors were stained weakly or not at all (Figures 3f and g ). Endothelial cells and infiltrating cells, such as lymphocytes and macrophages, were also strongly stained (Figures 3f  and g ), suggesting that evaluation of PTGER2 mRNA expression in whole NB samples might be affected by contamination with those normal tissue components.
Suppression of NB cell growth after restoration of PTGER2 expression To gain further insight into the potential role of PTGER2 loss in NB carcinogenesis, we investigated whether restoration of the gene product would suppress growth of NB cells lacking endogenous PTGER2. We used two kinds of PTGER2-expression constructs, a Myc-tagged full coding sequence of PTGER2 (pcDNA-PTGER2-Myc) and one without epitope tag (pcDNA-PTGER2), with a mock construct (pcDNA-mock) as a control. Two (SJ-N-CG) or three (GOTO) weeks after transfection and subsequent selection of drug-resistant colonies, the number of large colonies produced by PTGER2-transfected SJ-N-CG and GOTO cells decreased markedly compared to cells containing empty vector, regardless of the existence of myc-epitope in the C-terminus (Figure 4a and Supplementary Figure S2) . After transient transfection, typical apoptotic changes, such as condensation or fragmentation of nuclear chromatin, were observed more frequently in PTGER2-Myc-positive NB cells compared with either PTGER2-Myc-negative cells or control GFP-Myctransfected cells (Figure 4b ). Furthermore, stably PTGER2-transfected NB cells established from the SJ-N-CG and GOTO cell lines (Supplementary Figure  S3a) , showed a lower growth rate possibly in a PTGER2-expression level-dependent manner compared to cells transfected with control empty vector alone (mock, Figure 4c and Supplementary Figure S3b) .
Effects of PGE2, butaprost and 8-Bromo-cAMP (8-Br-cAMP) on growth of NB cells Since PTGER2 mediates a part of PGE2 signaling (Narumiya et al., 1999) , we examined whether PGE2 would affect growth of NB cells expressing PTGER2, using stable PTGER2 transfectants of SN-J-CG and their control counterparts (empty-vector clones). Since transfectants established from GOTO cells were not resistant to culture with serum concentrations lowered to p1% to reduce the effect of native PGE2 in serum, only SN-J-CG transfectants were available for the experiment. In mock transfectants, as in the DLD-1 colon-cancer cell line in which butaprost promoted cell growth (Castellone et al., 2005) , treatment with PGE2
for 72 h induced an increase in cell growth compared to treatment with vehicle alone (Figure 5a ). In cells stably expressing PTGER2, on the other hand, almost no increase in cell growth was observed after treatment with PGE2 compared with vehicle alone, suggesting that growth of NB cells might be accelerated by signaling mediated through receptors for PGE2 other than PTGER2, but inhibited by signaling through PTGER2.
To confirm this hypothesis we examined growth of stable PTGER2 transfectants after treatment with a PTGER2-specific agonist, butaprost. The number of SJ-N-CG cells stably expressing PTGER2 was dramatically decreased after 72-h incubation with butaprost compared with vehicle alone, while the number of mocktransfected cells showed almost no change (Figure 5b ), suggesting that signaling mediated by PTGER2, but not by other subtypes of PGE2 receptors, might specifically inhibit growth of NB cells. The same doses of butaprost promoted growth of the DLD-1 cell line. We performed fluorescence-activated cell sorting (FACS) analysis to analyse further the mechanism behind the antiproliferative effect of butaprost on NB cells. Butaprost treatment resulted in accumulation in the sub-G 1 phase of SJ-N-CG cells stably expressing PTGER2 (Figure 5c ), suggesting that butaprost exerts its growth-inhibitory effect at least partly through induction of apoptosis mediated by PTGER2. Butaprost-induced apoptotic changes in SJ-N-CG cells stably expressing PTGER2 were also confirmed by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) assay (Figure 5d ). Under low-serum condition without butaprost treatment, stable PTGER2 transfectants resulted in an accumulation of cells in G 0 -G 1 and a decrease in S and G 2 /M phase cells compared with control counterparts (Figure 5c ), suggesting that PTGER2 protein may arrest NB cells at the G 1 -S checkpoint (G 0 -G 1 arrest). However, no significant increase in the sub-G 1 phase was observed in stable PTGER2 transfectants compared with control counterparts (Figures 5c and d) .
Since PTGER2 couples to G proteins and increases the intracellular concentration of cAMP (Narumiya et al., 1999) , we postulated that increased intracellular cAMP might play a role in inhibiting growth of NB cells. To test this hypothesis, we examined whether stimulation of PTGER2 would induce elevation of intracellular cAMP content in stable PTGER2 transfectants of the SJ-N-CG cell line. After treatment with butaprost, a distinct increase in cAMP was observed in these transfectants, whereas no increase in cAMP occurred in mock transfectants (Figure 5b ). We further examined whether increasing intracellular cAMP using a cAMP analog, 8-Br-cAMP, would mimic the effect of butaprost on growth of NB cells. Growth of GOTO and SJ-N-CG cells, which lack expression of PTGER2, was inhibited by 8-Br-cAMP, whereas growth of SJ-N-KP and KP-N-SIFA, which express PTGER2, showed almost no change (Figure 6a ). FACS analysis showed accumulation of GOTO and SJ-N-CG cells in the sub-G 1 phase after treatment with 8-Br-cAMP (Figure 6a ).
Discussion
In a previous study (Misawa et al., 2005) , we identified the PTGDR and PTGER2 genes as possible targets for PTGER2 is a possible neuroblastoma suppressor Y Sugino et al histone modification, especially in MYCN-amplified cells. Methylation of PTGER2 was also observed in advanced primary NB tumors, although its direct correlation with expression status in primary NBs remains unclear due to high expression levels of PTGER2 in unavoidable nontumor cells. Growth of NB cell lines lacking expression of PTGER2 was inhibited by exogenous restoration of the gene product. Moreover, a PTGER2-specific agonist inhibited growth of transfected NB cell lines that were stably expressing exogenous PTGER2, at least in part through production of cAMP as a second messenger in those cells.
PTGER2 locates in 14q22.1, a chromosomal region that is involved in loss of heterozygosity (LOH) or copynumber losses in 20-25% of NBs, although the smallest region of overlapping LOH at 14q is more distal (14q23-qter; Thompson et al., 2001) . Indeed, most of the cell lines we used in this study showed normal copy numbers The putative 'core promoter region' of PTGER2, which showed high promoter activity in our reporter assay, was not methylated in some of the NB cell lines we analysed regardless of the gene's expression status, although aberrant DNA methylation in exonic region (Region 3) of PTGER2 was inversely correlated with expression in NB cell lines. On the other hand, within the putative 'core promoter region' the acetylation status of H3 and H4 histones, and the di-and trimethylation status of H3K9, were positively and inversely correlated with PTGER2 expression, respectively. In view of these observations, we speculate that silencing of PTGER2 in NB cells depends on integrated epigenetic events such as DNA methylation and histone modification. This phenomenon has been observed in other genes, including tumor-suppressor genes among a variety of solid tumors (Nakagawachi et al., 2003; Stirzaker et al., 2004; Strunnikova et al., 2005; Frigola et al., 2006; Yamada et al., 2006) .
Epigenetic mechanisms of tumor-suppressor-gene silencing in cancer remains incompletely understood (Jones and Baylin, 2002) . It is believed that DNA sequences in entire CpG islands with promoter activity are methylated, H3 and H4 are unacetylated and H3K9 is methylated. However, it was also reported that hypermethylation of nonpromoter exonic sequences affects heterochromatinization and local gene silencing (Frigola et al., 2006) . In some cancer-associated gene silencing, moreover, sequences outside the promoter region may be methylated first ( PTGER2 is a possible neuroblastoma suppressor Y Sugino et al Nakagawachi et al., 2003; Stirzaker et al., 2004; Strunnikova et al., 2005; ) , and this methylation could induce histone modifications such as deacetylation of lysine residues by histone deacetylase and H3K9 di-and tri-methylation by histone methyltransferase (Kondo et al., 2003; Stirzaker et al., 2004; Strunnikova et al., 2005) , mediated by methyl-CpG-binding proteins. These processes lead to condensation of the chromatin, which propagates into a transcription factor-binding region, making target sequences inaccessible to transcription factors; finally gene transcription is shut off (Jones and Baylin, 2002; Nakagawachi et al., 2003) . Consequently, methylation outside the promoter region could lead gene silencing indirectly, although histone modification within the critical promoter region may contribute to silencing directly. This scenario is consistent with our results showing that TSA alone can partially restore expression of PTGER2 and that TSA and 5-aza-dCyd exert a synergistic effect on restoring expression of this gene.
Using primary NB tumors, we showed that PTGER2 methylation within Region 3 occured more frequently in aggressive NBs such as stage 4 tumors than early-stage tumors, and in tumors with MYCN amplification than tumors without its amplification. Therefore the methylation status of this gene might be useful for predicting the aggressiveness of NB tumors, although our set of tumors was not suitable for survival analysis because few of the patients died during the follow-up period. Since PTGER2 is expressed in nontumorous cells, such as endothelial cells, and also in infiltrating lymphocytes and macrophages, it will be difficult to evaluate correlation between silenced PTGER2 expression and methylation status of NB cells in clinical samples. To clarify the clinical significance of the PTGER2 gene in NB, further examination of methylation status, not expression status, of this gene in a larger set of primary cases of NB will be required.
One of the most striking findings in the study reported here is that restoration of PTGER2 protein by either transient or stable transfection of expression constructs inhibited growth of NB cells that lacked endogenous PTGER2. Moreover, a PTGER2-specific agonist (butaprost) inhibited growth of NB cells stably expressing exogenous PTGER2, at least partly by inducing apoptosis. Those results suggested that negative regulation of cell growth, including induction of apoptosis, was a significant consequence of ectopic expression of PTGER2 in NB cells lacking expression of this gene.
PGE2 is biosynthesized from arachidonic acid as a major cyclo-oxygenase product in a number of physiological settings, and produces a broad range of biologic actions in diverse tissues (Narumiya et al., 1999) . It was shown that cyclo-oxygenase-2 (COX-2) is expressed in NB, and COX-inhibiting nonsteroidal anti-inflammatory drugs inhibit growth of NB cells in vitro and in vivo (Johnsen et al., 2004) . In some tumors, including colon cancer, PGE2 has been implicated in promotion of tumor growth, promotion of angiogenesis, inhibition of apoptosis, stimulation of invasion, or suppression of immune responses (Hoshino et al., 2003; Hata and Breyer, 2004; Castellone et al., 2005; Wang et al., 2005a Wang and DuBois, 2006) . Those activities indicate that genes encoding receptors for PGE2 and/or its downstream targets can act as oncogenes. However, PGE2 can also act anti-proliferatively in some tumors, inducing apoptosis or differentiation (Santoro et al., 1977; Fulton et al., 1989; Fedyk et al., 1996; Okuyama et al., 2002) , indicating that receptors for PGE2 and/or its downstream targets also can function as tumor suppressors.
Signaling of PGE2 is mediated by four receptors (PTGRE 1-4) ; the physiological/pathophysiological behavior of PGE2 appears to depend on the type of its receptors and on downstream pathways, accounting for completely opposite effects (Narumiya et al., 1999) . Although an antiapoptotic effect of PTGER2 in gastric mucosal cells (Hoshino et al., 2003) and a growthpromoting effect in colon-cancers via the PTGER2-G saxin-b-catenin signaling pathway (Castellone et al., 2005) have been reported, several lines of evidence show that PTGER2 also can negatively regulate cell growth and induce apoptosis and/or differentiation in various types of cells (Fedyk et al., 1996; Suda et al., 1996; Okuyama et al., 2002) . Thus, the role played by the PGE2-PTGER2 signaling pathway may vary considerably from one neoplasm to another, probably in a tissue-or cell lineage-dependent manner. This hypothesis is consistent with our results demonstrating that butaprost promoted cell growth in colon-cancer cell line DLD-1, as expected on the basis of published data (Castellone et al., 2005) , but inhibited growth of NB cells stably expressing PTGER2. In NB, disruption of the PTGER2-mediated growth-suppressive pathway may contribute to tumor progression.
The question of how the cellular context is able to determine the action of PGE2-PTGER2 signaling in NB cells is extremely interesting and deserves further investigation. PGE2 increases intracellular concentrations of cAMP through PTGER2 and PTGER4 and some splice variants of PTGER3, coupling to G proteins (Narumiya et al., 1999) . Among PGE2 receptors, PTGER2 has the most potential for elevating intracellular cAMP concentrations (Regan, 2003) . Since elevated levels of cAMP are associated with decreased proliferation and increased differentiation or apoptosis in several types of cells including glioblastoma cells (Chen et al., 1998) , esophageal squamous cell carcinomas (Wang et al., 2005b) , and hippocampal cells (Takadera et al., 2004) , we speculate that PTGER2-mediated production of intracellular cAMP may contribute to the growth-inhibitory effect of restored PTGER2 in NB cells lacking endogenous expression of the gene. In our experiments a PTGER2-specific agonist increased intracellular cAMP levels and exerted growth inhibitory effects, at least partly by inducing apoptosis, in stable PTGER2 transfectants established from the SJ-N-CG cell line, although G 0 -G 1 arrest but not apoptosis was predominantly observed in PTGER2 transfectants under low-serum condition without butaprost treatment. A similar effect of butaprost in hippocampal cells has been reported (Takadera et al., , even though those cells were nontumorous. The fact that a cAMP analog, 8-Br-cAMP, which directly increases intracellular cAMP, inhibited cell growth and induced apoptosis in NB cells lacking endogenous PTGER2, but not in those expressing PTGER2, suggested that NB cells may lose responsiveness to PTGER2-mediated growth inhibition/apoptosis through epigenetic silencing of PTGER2 (I in Figure 6b ) or by disruption of a downstream cAMP-dependent signaling pathway (II in Figure 6b ). Further examination will be needed to clarify the biological and clinical significance of the PGE2-PTGER2-cAMP signaling pathway in the pathogenesis of NB, especially with regard to the resistance of advanced NB tumors to apoptosis (del Carmen Mejia et al., 2002) .
Materials and methods
Cell culture and primary tissue samples . The DLD-1 colon-cancer cell line was purchased from the Japanese Collection of Research Bioresources (Osaka, Japan). Cells were maintained in RPMI-1640, supplemented with 10% fetal bovine serum (FBS) and 100 U/ml penicillin/100 mg/ml streptomycin. NB cells were treated with or without 1 or 5 mM of 5-aza-dCyd for 5 days, and/or 100 ng/ml of TSA for the last 12 h. Primary tumor samples were obtained at surgery from 49 patients with NB and two with ganglioneuroma who underwent tumor resection at University Hospital, Kyoto Prefectural University of Medicine from 1986 to 2003, with written consent from the parents of each patient in the formal style and after approval by the local ethics committees. Staging of each NB case was determined according to the criteria of the International Neuroblastoma Staging System (Brodeur et al., 1993) . Of the 49 NB patients, 41 (83.7%) were infants less than 18 months of age at diagnosis, 36 (73.5%) were detected by a mass-screening program, 12 were classified as stage 1, 11 as stage 2, nine as stage 3, 12 as stage 4 and five as stage 4S; MYCN amplification was detected in the tumors of nine (18.4%) patients. Genomic DNA was available for analysis from all 49 NB and two ganglioneuroma samples; total RNA was available from 39 NB samples.
Reagents and plasmids PGE2, butaprost and 8-Br-cAMP were obtained respectively from Calbiochem (San Diego, CA, USA), Cayman Chemicals (Ann Arbor, MI, USA) and Sigma-Aldrich (St Louis, MO, USA). Anti-PTGER2 polyclonal antibody was from Cayman Chemicals. Anti-acetylated histone H3 (anti-AcH3), antiacetylated histone H4 (anti-AcH4), anti-dimethylated histone H3 lysine 9 (anti-2Me-H3K9) and anti-trimethylated histone H3 lysine 9 (anti-3Me-H3K9) antibodies were from Upstate (Lake Placid, NY, USA); anti-Myc-tag and anti-p44/42 antibodies were from Cell Signaling Technology (Beverly, MA, USA).
Plasmids expressing PTGER2 alone (pcDNA3.1-PTGER2) C-terminally Myc-tagged PTGER2 (pcDNA3.1-PTGER2-Myc) were prepared by cloning the RT-PCR product of the full coding sequence of PTGER2 alone, or in-frame along with the Myc-epitope in the C terminus, respectively, into the vector pcDNA3.1 (Invitrogen, Carlsbad, CA, USA). The empty vector pcDNA3.1 or plasmid expressing Myc-tagged GFP (pcDNA3.1-GFP-Myc) was used as a control.
RT-PCR and real-time quantitative RT-PCR Single-stranded cDNAs generated from total RNAs were amplified with primers specific for each gene (Supplementary Table S1 ). The glyceraldehyde-3-phosphate dehydrogenase gene (GAPDH) was amplified at the same time to allow estimation of the efficiency of cDNA synthesis. RT-PCR products were electrophoresed, and quantified with LAS-3000 (Fujifilm, Tokyo, Japan). Levels of mRNA expression in primary tumors were measured using a quantitative real-time fluorescence detection method (PRISM 7900HT, Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. The expression of PTGER2 mRNA in each sample was normalized on the basis of the respective GAPDH content and recorded as a relative expression level. PCR amplification was performed in duplicate for each sample.
Methylation analysis
Genomic DNAs were treated with sodium bisulfite, and subjected to PCR using primer sets designed to amplify regions of interest (Supplementary Table S1 ). For COBRA, PCR products were digested with TaqI, and electrophoresed (Xiong and Laird, 1997) . For bisulfite sequencing, the PCR products were subcloned and then sequenced.
For MSP, sodium bisulfite-treated DNA was amplified using primers specific to the methylated and unmethylated forms of DNA sequences (Supplementary Table S1 ). DNAs from cell lines recognized as unmethylated or highly methylated by bisulfite sequencing were used as controls.
Promoter assay DNA fragments around the CpG-island predicted by the CpGPLOT program (http://www.ebi.ac.uk/emboss/cpgplot/) were ligated into the vector pGL3-Basic (Promega, Madison, WI, USA). Promoter assay using each construct or control vector with an internal control vector (pRL-hTK, Promega) was performed as described elsewhere (Misawa et al., 2005) .
ChIP assay
ChIP assays were performed as described previously (Sonoda et al., 2004) . Chromatin was immunoprecipitated with antiAcH3, anti-AcH4, anti-2Me-H3K9, anti-3Me-H3K9, or no antibody, after which a quantitative real-time PCR was performed with 1/30 of the immunoprecipitated DNA, using primers designed to amplify regions of interest (Supplementary  Table S1 ); 1/600 of the solution before adding antibody was amplified as an internal control for the amount of DNA.
Immunohistochemistry Formalin-fixed, paraffin-embedded surgical specimens were sliced into 5 mm-thick sections, deparaffinized, then immersed for 30 min in methanol containing 0.3%. hydrogen peroxide. After retrieval of epitope by boiling, the sections were incubated with anti-PTGER2 antibody (1:500 dilution) and then with a biotinylated secondary antibody (1:200 dilution; Vector Laboratories, Burlingame, CA, USA). After staining with Vectastain ABC reagent (Vector Laboratories), the sections were immersed in 0.05% diaminobenzidine tetrahydrochloride solution containing 0.01% hydrogen peroxide, and counterstained with hematoxylin.
Transient transfection and colony-formation assays pcDNA3.1-PTGER2, pcDNA3.1-PTGER2-Myc or the emptyvector (pcDNA3.1-mock) were transiently transfected into SJ-N-CG and GOTO cells using FuGENE6 (Roche Diagnostics, Tokyo, Japan) for colony-formation assays. Expression of PTGER2 protein in transfected cells was confirmed by western blotting, using anti-Myc-Tag or anti-PTGER2 antibody as described elsewhere (Misawa et al., 2005) . After 2-3 weeks of incubation with G418 (600 and 250 mg/ml for SJ-N-CG and GOTO, respectively), cells were stained with crystal violet.
Immunofluorescent staining
Transiently or stably transfected cells seeded into slide chambers were fixed in cold methanol for 3 min. The cells were covered with blocking solution (1% skim milk in phosphate-buffered saline) for 30 min, and incubated overnight at 41C with anti-Myc-tag antibody (1:200 dilution) in blocking solution. There followed 1 h of incubation with Alexa 594-conjugated goat anti-mouse IgG (1:500 dilution; Molecular Probes, Eugene, OR, USA). The cells were counterstained with 4 0 ,6-diamidino-2-phenylindole, and viewed with an ECLIPSE E800 fluorescence microscope (Nikon, Tokyo, Japan).
Establishment of stable transfectants and cell-growth assay Stable transfectants of PTGER2 and mock vector were obtained by transfecting pcDNA3.1-PTGER2-Myc. and pcDNA3.1-mock, respectively, into SJ-N-CG and GOTO cells, and selected by G418. For measurements of cell growth, 2 Â 10 3 cells were seeded in 96-well plates. To determine the effects of PGE2, butaprost, or 8-Br-cAMP on growth of NB cells, wild type cell lines or stable transfectants of SJ-N-CG cells were treated with various concentrations of each reagent for 72 h, after 24-h preculture in media containing 1% FBS (for PGE2 and butaprost) or 10% FBS (for 8-Br-cAMP). The numbers of viable cells were assessed by a colorimetric watersoluble tetrazolium salt (WST) assay as described elsewhere (Misawa et al., 2005) . The DLD-1 cell line was served as a positive control for the PGE2 and butaprost experiments (Castellone et al., 2005) .
Enzyme immunoassay
After 24-h pre-culture in medium containing 1% FBS, stable transfectants of SJ-N-CG cells were treated with 0 or 5 mM of butaprost for 20 min. Intracellular cAMP was measured by means of a cAMP Enzyme immunoassay (EIA) system (GE Healthcare Bio-Sciences, Piscataway, NJ, USA) according to the manufacturer's protocol.
Flow cytometry
Stable transfectants of SJ-N-CG cells were treated with butaprost (5 mM) or 8-Br-cAMP (0.1 or 1 mM) for 72 h. For FACS analysis, harvested cells were fixed in 70% cold ethanol before treatment with RNaseA and propidium iodide. Samples were analysed on a FACSCalibur HG (Becton-Dickinson, San Jose, CA, USA). Data were analysed using BD CellQuest Pro (Becton-Dickinson).
TUNEL stain
Wild-type or stable transfectants of SJ-N-CG cells were treated with or without butaprost or 8-Br-cAMP, and apoptosis was detected by enzymatic labeling of DNA strand-breaks using a TUNEL staining kit (MEBSTAIN Apoptosis Kit Direct; MBL, Aichi, Japan) according to the manufacturer's protocol.
